SRRA Insider Trading Activity and SEC Form 4 Filings
SRRA insider trading summary
No open-market insider purchases or sales of Sierra Oncology, Inc. (SRRA) have been reported on SEC Form 4 in the past 12 months.
Latest SRRA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 6, 2022 | William D. Turner | Chief Reg & Tech Ops Officer | Sell | $236K (6,347 @ $37.25) |
| Apr 5, 2022 | William D. Turner | Chief Reg & Tech Ops Officer | Sell | $4K (100 @ $37.09) |
| Apr 4, 2022 | Mary Christina Thomson | General Counsel, CCO & Sec'y | Sell | $70K (2,000 @ $35.14) |
| Mar 18, 2022 | William D. Turner | Chief Reg & Tech Ops Officer | Sell | $4K (100 @ $37.05) |
| Mar 17, 2022 | William D. Turner | Chief Reg & Tech Ops Officer | Sell | $128K (3,453 @ $37.06) |
| Mar 4, 2022 | Mary Christina Thomson | General Counsel, CCO & Sec'y | Sell | $61K (2,000 @ $30.60) |
| Feb 7, 2022 | William D. Turner | Chief Reg & Tech Ops Officer | Sell | $323K (10,000 @ $32.32) |
| Feb 4, 2022 | Mary Christina Thomson | General Counsel, CCO & Sec'y | Sell | $60K (2,000 @ $29.78) |
| Feb 2, 2022 | Joshua Richardson | Director | Buy | $4.7M (175,000 @ $27.00) |
| Feb 2, 2022 | Longitude Venture Partners III, L.P. | 10% Owner | Buy | $4.7M (175,000 @ $27.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.